These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 36546701)
1. To wait, or too late? Modeling the effects of delayed ofatumumab treatment in relapsing-remitting multiple sclerosis. Montgomery SM; Green L; Karoui H; Nicholas R; Loh J J Med Econ; 2023; 26(1):139-148. PubMed ID: 36546701 [TBL] [Abstract][Full Text] [Related]
2. Cost-utility of fingolimod compared with dimethyl fumarate in highly active relapsing-remitting multiple sclerosis (RRMS) in England. Maruszczak MJ; Montgomery SM; Griffiths MJ; Bergvall N; Adlard N J Med Econ; 2015; 18(11):874-85. PubMed ID: 26055952 [TBL] [Abstract][Full Text] [Related]
3. The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada. Su W; Kansal A; Vicente C; Deniz B; Sarda S J Med Econ; 2016 Jul; 19(7):718-27. PubMed ID: 27080475 [TBL] [Abstract][Full Text] [Related]
4. Real-world disease-modifying therapy usage in persons with relapsing-remitting multiple sclerosis: Cross-sectional data from the Swiss Multiple Sclerosis Registry. Bossart J; Kamm CP; Kaufmann M; Stanikić M; Puhan MA; Kesselring J; Zecca C; Gobbi C; Rapold I; Kurmann R; Ammann S; von Wyl V; Mult Scler Relat Disord; 2022 Apr; 60():103706. PubMed ID: 35228114 [TBL] [Abstract][Full Text] [Related]
5. Comparative effectiveness and safety of ozanimod Paul D; Swallow E; Patterson-Lomba O; Branchcomb T; N'Dri L; Gomez-Lievano A; Liu J; Dua A; McGinley M Ther Adv Neurol Disord; 2024; 17():17562864241237856. PubMed ID: 38855023 [TBL] [Abstract][Full Text] [Related]
6. When does economic model type become a decisive factor in health technology appraisals? Learning from the expanding treatment options for relapsing-remitting multiple sclerosis. Noon KM; Montgomery SM; Adlard NE; Kroes MA J Med Econ; 2018 Oct; 21(10):983-992. PubMed ID: 29923439 [TBL] [Abstract][Full Text] [Related]
8. Evaluating the impact of early vs delayed ofatumumab initiation and estimating the long-term outcomes of ofatumumab vs teriflunomide in relapsing multiple sclerosis patients in Spain. Vudumula U; Patidar M; Gudala K; Karpf E; Adlard N J Med Econ; 2023; 26(1):11-18. PubMed ID: 36472139 [TBL] [Abstract][Full Text] [Related]
9. Cost-utility of First-line Disease-modifying Treatments for Relapsing-Remitting Multiple Sclerosis. Soini E; Joutseno J; Sumelahti ML Clin Ther; 2017 Mar; 39(3):537-557.e10. PubMed ID: 28209373 [TBL] [Abstract][Full Text] [Related]
10. Stick or twist? Cost-effectiveness of siponimod compared with continuing existing disease-modifying therapies in the treatment of active secondary progressive multiple sclerosis in the UK. Montgomery S; Woodhouse F; Vudumula U; Gudala K; Duddy M; Kroes M J Med Econ; 2022; 25(1):669-678. PubMed ID: 35575251 [TBL] [Abstract][Full Text] [Related]
12. Cost-consequence analysis of ofatumumab for the treatment of relapsing-remitting multiple sclerosis in Canada. Bhan V; Clift F; Baharnoori M; Thomas K; Patel BP; Blanchette F; Adlard N; Vudumula U; Gudala K; Dutta N; Grima D; Mouallif S; Farhane F J Comp Eff Res; 2023 Sep; 12(9):e220175. PubMed ID: 37606897 [No Abstract] [Full Text] [Related]
13. Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study. Lanzillo R; Moccia M; Palladino R; Signoriello E; Carotenuto A; Maniscalco GT; Saccà F; Bonavita S; Russo CV; Iodice R; Petruzzo M; Sinisi L; De Angelis M; Lavorgna L; De Rosa A; Romano F; Orlando V; Ronga B; Florio C; Lus G; Brescia Morra V Mult Scler Relat Disord; 2020 Feb; 38():101871. PubMed ID: 31786463 [TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing forms of multiple sclerosis in the United States. Mauskopf J; Fay M; Iyer R; Sarda S; Livingston T J Med Econ; 2016; 19(4):432-42. PubMed ID: 26707273 [TBL] [Abstract][Full Text] [Related]
15. The budget impact of introducing delayed-release dimethyl fumarate for treatment of relapse-remitting multiple sclerosis in Canada. Dorman E; Kansal AR; Sarda S J Med Econ; 2015; 18(12):1085-91. PubMed ID: 26390149 [TBL] [Abstract][Full Text] [Related]
16. Real world comparison of teriflunomide and dimethyl fumarate in naïve relapsing multiple sclerosis patients: Evidence from the Italian MS register. Zanghì A; Avolio C; Amato MP; Filippi M; Trojano M; Patti F; Amico E; Mult Scler Relat Disord; 2022 Feb; 58():103489. PubMed ID: 35032879 [TBL] [Abstract][Full Text] [Related]
17. Medication adherence and health outcomes in persons with multiple sclerosis treated with dimethyl fumarate. Jožef M; Locatelli I; Brecl Jakob G; Rot U; Kos M Mult Scler Relat Disord; 2023 Apr; 72():104615. PubMed ID: 36933300 [TBL] [Abstract][Full Text] [Related]